EGFR-targeted liposomal nanoparticles (EGFR-LP) were developed for the treatment of NSCLC resistance to drugs as erlotinib and afatinib, determined by mutations in the tyrosine kinase (TK) domain of EGFR [146]. The gene discussed is TKT; the disease is non-small cell lung carcinoma.